These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 17062718

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 3. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
    Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J.
    Breast Cancer Res; 2006 Jul; 8(2):R13. PubMed ID: 16542503
    [Abstract] [Full Text] [Related]

  • 4. [The role of bisphosphonates of adjuvant therapy in breast cancer].
    Gálvez-Muñoz E, Rodríguez-Lescure Á.
    Med Clin (Barc); 2010 Jun 12; 135(2):70-4. PubMed ID: 20022069
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S.
    Can J Oncol; 1995 Dec 12; 5 Suppl 1():54-7. PubMed ID: 8853526
    [Abstract] [Full Text] [Related]

  • 7. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E.
    Bull Cancer; 2001 Jul 12; 88(7):701-7. PubMed ID: 11495824
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of bisphosphonates in early breast cancer.
    Paterson AH.
    Oncologist; 2006 Jul 12; 11 Suppl 1():13-9. PubMed ID: 16971735
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A.
    Breast Cancer Res Treat; 2010 Aug 20; 122(3):627-36. PubMed ID: 20490653
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J, Tripathy D.
    J Pain Symptom Manage; 2007 Apr 20; 33(4):462-72. PubMed ID: 17397707
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates: clinical experience.
    Coleman RE.
    Oncologist; 2004 Apr 20; 9 Suppl 4():14-27. PubMed ID: 15459426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.